查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1967732

心內膜切片檢查市場 - 全球產業規模、佔有率、趨勢、機會、預測：按產品、高級零件、最終用途、地區和競爭對手分類，2021-2031 年

Endomyocardial Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Tip, By End-Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球心肌切片檢查市場預計將從 2025 年的 3.7168 億美元成長到 2031 年的 5.4941 億美元，複合年成長率為 6.73%。

心肌切片切片檢查是一種侵入性診斷方法，它使用切片檢查鉗取少量心肌組織樣本，是識別移植患者同種異體移植排斥反應和診斷某些心肌病的重要技術。市場成長的主要促進因素是全球心臟衰竭患者數量的增加以及心臟移植手術數量的上升，這些手術需要頻繁的術後後續觀察以確保移植器官的存活。此外，導管引導系統的不斷進步和切片檢查鉗安全性的提高也持續支持著此診斷方法在臨床上的應用。

市場概覽
預測期 2027-2031
市場規模：2025年 3.7168億美元
市場規模：2031年 5.4941億美元
複合年成長率：2026-2031年 6.73%
成長最快的細分市場 鉗子
最大的市場 北美洲

根據國際心肺移植協會的數據，2024年全球共進行了超過6,000例心臟移植手術。如此龐大的手術量直接推動了對切片檢查器械的需求，因為患者在移植後的關鍵第一年通常需要多次後續觀察切片檢查。儘管需求穩定，但由於該技術的侵入性，市場仍面臨許多挑戰。諸如心臟穿孔等併發症的風險促使人們更加關注磁振造影（MRI）等非侵入性診斷方法的研發。

市場促進因素

全球心臟移植手術數量的不斷成長是推動市場擴張的主要動力。這些手術需要嚴格的術後監測，以識別移植排斥反應。心肌內切片檢查是目前公認的臨床標準方法，在每次移植手術後，患者復原過程中都會反覆使用該儀器。根據美國器官移植網路（UNOS）2024年1月的數據，2023年美國共進行了4,519例心臟移植手術。如此高的數字凸顯了對監測的高需求，而這一趨勢在全球範圍內普遍存在。例如，英國國家醫療服務體系（NHS）血液和移植機構的一份報告顯示，截至2024年底，英國心臟移植等待名單上有328名患者，這凸顯了心臟科需要持續保持強大的切片檢查能力，以滿足未來患者的需求。

同時，隨著心肌炎和心肌病發病率的上升，精確的組織學特徵分析對於制定治療策略至關重要。當非侵入性影像學檢查無法確定心臟衰竭的病因時，醫生不得不依賴組織取樣來鑑別諸如心臟類澱粉沉積症和鉅細胞性心肌炎等複雜疾病。根據美國心臟協會2024年1月報告，目前美國約有670萬成年人患有心臟衰竭。如此沉重的疾病負擔凸顯了診斷性切片檢查的持續必要性，醫生也越來越依賴組織學分析來確定不明原因心臟功能障礙患者的最佳治療方案。

市場挑戰

全球心肌切片檢查市場的主要障礙在於其侵入性，嚴重阻礙了其廣泛應用。採集心肌組織本身就存在嚴重併發症的風險，包括心律不整、瓣膜損傷和心臟穿孔。這些安全隱患常常導致臨床醫師在建議進行臨床後續觀察的情況下，也不願意頻繁進行切片檢查。因此，醫療機構越來越重視非侵入性診斷方法，例如磁振造影（MRI）。 MRI 是一種更安全的方法，可以在不進行組織採集的情況下識別病變，避免了相關併發症。

這些營運限制直接限制了市場利用心血管疾病日益成長的趨勢的能力。根據美國心臟衰竭協會統計，到2024年，美國將有約670萬成年人患有心臟衰竭。儘管如此巨大的疾病負擔為診斷監測提供了廣泛的潛在市場，但切片檢查相關的風險使得這種方法難以成為日益成長的患者群體的常規標準治療手段。因此，該市場目前僅限於小規模部分病情嚴重的患者，在這些患者中，侵入性風險被認為是可接受的，從而限制了其整體成長潛力。

市場趨勢

基因組和分子層面的排斥反應監測正在從根本上改變全球心肌切片檢查市場，將臨床標準從固定的檢測方案轉變為標靶監測。醫療服務提供者不再讓心臟移植患者頻繁接受侵入性檢查，而是擴大採用非侵入性液態生物檢體來篩檢移植損傷，並將組織取樣限制在分子標記升高的患者中。這種通訊協定的改變顯著減少了不必要的手術次數，同時密切監測移植器官的健康狀況。例如，CareDx公司在2024年5月發布的一份關於SHORE註冊研究的新聞稿指出，與傳統的切片檢查主導的通訊協定相比，採用多方面分子監測後，心臟科醫生在移植兩年後進行的切片檢查次數減少了40%。

同時，人工智慧增強型數位病理工作流程的引入正在革新術後分析階段，消除切片檢查解讀中的一個主要瓶頸：組織學變異性。透過從人工顯微鏡檢查轉向數位化切片掃描與深度學習演算法的結合，檢查室可以自動測量淋巴細胞浸潤等排斥標誌物，從而確保不同心臟中心之間診斷結果的一致性。這種技術融合提升了每次切片檢查的臨床價值，並透過更優的數據收集驗證了侵入性操作的有效性。根據《CAP TODAY》2024年12月的一篇報導報道，臨床檢查室採用數位病理解決方案的比例已達到約10%，這表明自動化診斷正顯著向高精度組織分析轉型。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球心內膜切片檢查市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品分解（鑷子、配件）
    • 筆尖形狀（超彎、直尖、預彎、其他）
    • 按用途（醫院、門診手術中心、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美心內膜切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲心內膜切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區心內膜切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲心內膜切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲心內膜切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球心內膜切片檢查市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Argon Medical Devices Inc.
  • Cordis
  • Mermaid Medical Group
  • Terumo Corp.
  • Scholten Surgical Instruments, Inc.
  • Changzhou Toolmed Medical Instrument Co., Ltd.
  • Fehling Surgical Instruments Inc.
  • SternMed GmbH
  • Olympus Corporation of the Americas
  • Heart Medical Europe BV

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23936

The Global Endomyocardial Biopsy Market is projected to expand from USD 371.68 Million in 2025 to USD 549.41 Million by 2031, growing at a CAGR of 6.73%. As an invasive diagnostic procedure, endomyocardial biopsy involves using a bioptome to extract small samples of heart muscle tissue, serving as a critical method for identifying allograft rejection in transplant patients and diagnosing specific cardiomyopathies. The market is primarily fueled by the increasing global rates of heart failure and the associated rise in heart transplantation surgeries, which require frequent post-operative monitoring to ensure graft viability. Additionally, ongoing advancements in catheter guidance systems and the safety of biopsy forceps continue to support the utilization of this diagnostic standard within clinical environments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 371.68 Million
Market Size 2031USD 549.41 Million
CAGR 2026-20316.73%
Fastest Growing SegmentForceps
Largest MarketNorth America

According to the International Society for Heart and Lung Transplantation, over 6,000 heart transplant operations were conducted globally in 2024. This volume of procedures directly sustains the demand for biopsy instruments, as patients typically require multiple surveillance biopsies during the crucial first year following transplantation. Despite this consistent demand, the market encounters significant obstacles due to the invasive nature of the technique; the potential risks of complications, such as cardiac perforation, are driving interest in and development of non-invasive diagnostic options like cardiac magnetic resonance imaging.

Market Driver

The growing number of heart transplant procedures worldwide serves as the main engine for market expansion, as these surgeries require strict post-operative monitoring to identify allograft rejection. Because endomyocardial biopsy is the established clinical standard for this purpose, every transplant generates a recurring necessity for device usage throughout a patient's recovery process. Data from the United Network for Organ Sharing in January 2024 highlighted that healthcare providers completed 4,519 heart transplants in the United States in 2023. This high volume reinforces the demand for surveillance, a pattern observed globally; for instance, NHS Blood and Transplant reported that the active heart transplant waiting list in the United Kingdom included 328 patients by the end of 2024, signaling continued pressure on cardiac units to maintain strong biopsy capabilities for future patients.

At the same time, the rising prevalence of myocarditis and cardiomyopathies necessitates precise tissue characterization to direct treatment plans. When non-invasive imaging fails to clarify the cause of heart failure, doctors depend on tissue extraction to distinguish between complex disorders such as cardiac amyloidosis and giant cell myocarditis. As reported by the American Heart Association in January 2024, roughly 6.7 million adults in the United States currently suffer from heart failure. This significant burden of disease guarantees a continuous need for diagnostic biopsies, as physicians increasingly emphasize histological analysis to identify the best management approaches for patients with unexplained cardiac dysfunction.

Market Challenge

The central obstacle hindering the Global Endomyocardial Biopsy Market is the invasive character of the procedure, which presents a significant hurdle to widespread usage. Extracting heart muscle tissue involves intrinsic risks of serious complications, such as arrhythmias, valve damage, and cardiac perforation. These safety issues discourage clinicians from performing biopsies frequently, even in cases where longitudinal tracking is clinically advised. As a result, medical providers are progressively favoring non-invasive diagnostic substitutes, including cardiac magnetic resonance imaging, which provide safer methods for identifying pathologies without the morbidity risks linked to physical tissue removal.

This operational constraint directly limits the market's capacity to leverage the rising prevalence of cardiovascular diseases. According to the Heart Failure Society of America, approximately 6.7 million adults in the United States were living with heart failure in 2024. Although this extensive disease burden offers a vast addressable market for diagnostic monitoring, the dangers associated with biopsies prevent the technique from becoming the routine standard of care for this growing patient population. Consequently, the market is confined to a smaller segment of critical cases where the invasive risks are considered acceptable, thereby restricting overall growth potential.

Market Trends

The move toward genomic and molecular-based rejection monitoring is fundamentally transforming the Global Endomyocardial Biopsy Market by shifting the clinical standard from fixed procedural timetables to targeted surveillance. Rather than subjecting heart transplant patients to frequent invasive checks, healthcare providers are increasingly using non-invasive liquid biopsies to screen for graft injury, limiting tissue extraction to patients who exhibit elevated molecular markers. This change in protocol significantly lowers the total number of unnecessary procedures while ensuring strict monitoring of graft health; for example, a May 2024 press release from CareDx, Inc. regarding the SHORE registry noted that cardiologists performed 40% fewer biopsies in the second post-transplant year when using multimodal molecular surveillance compared to traditional biopsy-led protocols.

Concurrently, the adoption of AI-enhanced digital pathology workflows is modernizing the post-procedural analysis stage, resolving the major bottleneck of histological variability in interpreting biopsies. By moving from manual microscopy to digitized slide scanning combined with deep learning algorithms, labs can automate the measurement of rejection markers like lymphocyte infiltration, ensuring better diagnostic consistency across various cardiac centers. This technological convergence improves the clinical value of every biopsy, justifying the invasive nature of the procedure through superior data retrieval. According to an article in CAP TODAY from December 2024, the adoption rate of digital pathology solutions in clinical labs has reached roughly 10%, signaling a critical shift toward automated diagnostics that enable high-precision tissue analysis.

Key Market Players

  • Argon Medical Devices Inc.
  • Cordis
  • Mermaid Medical Group
  • Terumo Corp.
  • Scholten Surgical Instruments, Inc.
  • Changzhou Toolmed Medical Instrument Co., Ltd.
  • Fehling Surgical Instruments Inc.
  • SternMed GmbH
  • Olympus Corporation of the Americas
  • Heart Medical Europe BV

Report Scope

In this report, the Global Endomyocardial Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Endomyocardial Biopsy Market, By Product

  • Forceps
  • Accessories

Endomyocardial Biopsy Market, By Tip

  • Maxi-curved
  • Straight
  • Pre-curved
  • Others

Endomyocardial Biopsy Market, By End-Use

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Endomyocardial Biopsy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Endomyocardial Biopsy Market.

Available Customizations:

Global Endomyocardial Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Endomyocardial Biopsy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Forceps, Accessories)
    • 5.2.2. By Tip (Maxi-curved, Straight, Pre-curved, Others)
    • 5.2.3. By End-Use (Hospitals, Ambulatory Surgical Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Endomyocardial Biopsy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Tip
    • 6.2.3. By End-Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Endomyocardial Biopsy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Tip
        • 6.3.1.2.3. By End-Use
    • 6.3.2. Canada Endomyocardial Biopsy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Tip
        • 6.3.2.2.3. By End-Use
    • 6.3.3. Mexico Endomyocardial Biopsy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Tip
        • 6.3.3.2.3. By End-Use

7. Europe Endomyocardial Biopsy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Tip
    • 7.2.3. By End-Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Endomyocardial Biopsy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Tip
        • 7.3.1.2.3. By End-Use
    • 7.3.2. France Endomyocardial Biopsy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Tip
        • 7.3.2.2.3. By End-Use
    • 7.3.3. United Kingdom Endomyocardial Biopsy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Tip
        • 7.3.3.2.3. By End-Use
    • 7.3.4. Italy Endomyocardial Biopsy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Tip
        • 7.3.4.2.3. By End-Use
    • 7.3.5. Spain Endomyocardial Biopsy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Tip
        • 7.3.5.2.3. By End-Use

8. Asia Pacific Endomyocardial Biopsy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Tip
    • 8.2.3. By End-Use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Endomyocardial Biopsy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Tip
        • 8.3.1.2.3. By End-Use
    • 8.3.2. India Endomyocardial Biopsy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Tip
        • 8.3.2.2.3. By End-Use
    • 8.3.3. Japan Endomyocardial Biopsy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Tip
        • 8.3.3.2.3. By End-Use
    • 8.3.4. South Korea Endomyocardial Biopsy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Tip
        • 8.3.4.2.3. By End-Use
    • 8.3.5. Australia Endomyocardial Biopsy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Tip
        • 8.3.5.2.3. By End-Use

9. Middle East & Africa Endomyocardial Biopsy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Tip
    • 9.2.3. By End-Use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Endomyocardial Biopsy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Tip
        • 9.3.1.2.3. By End-Use
    • 9.3.2. UAE Endomyocardial Biopsy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Tip
        • 9.3.2.2.3. By End-Use
    • 9.3.3. South Africa Endomyocardial Biopsy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Tip
        • 9.3.3.2.3. By End-Use

10. South America Endomyocardial Biopsy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Tip
    • 10.2.3. By End-Use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Endomyocardial Biopsy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Tip
        • 10.3.1.2.3. By End-Use
    • 10.3.2. Colombia Endomyocardial Biopsy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Tip
        • 10.3.2.2.3. By End-Use
    • 10.3.3. Argentina Endomyocardial Biopsy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Tip
        • 10.3.3.2.3. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Endomyocardial Biopsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Argon Medical Devices Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Cordis
  • 15.3. Mermaid Medical Group
  • 15.4. Terumo Corp.
  • 15.5. Scholten Surgical Instruments, Inc.
  • 15.6. Changzhou Toolmed Medical Instrument Co., Ltd.
  • 15.7. Fehling Surgical Instruments Inc.
  • 15.8. SternMed GmbH
  • 15.9. Olympus Corporation of the Americas
  • 15.10. Heart Medical Europe BV

16. Strategic Recommendations

17. About Us & Disclaimer